SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Merck Discontinues Nemtabrutinib Program After Phase 3 Safety Review

Merck said it is discontinuing its nemtabrutinib program after a Phase 3 safety review.

MRK

Related stories